Provectus Biopharmaceuticals, Inc. (PVCT) shareholders
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jeffrey Allen Morris | 61,100,610 | 11.30% | 13G (passive) | Aug 12, 2024 |
| Pershing Edward | 52,441,275 | 11.61% | 13D (active) amendment | Jun 30, 2026 |
| Dominic Rodrigues | 25,220,549 | 5.67% | 13D (active) | Dec 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PVCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Home Federal Bank Of Tennessee | 100,000 | 0.02% | $6.90K | – | 0.00% |
| Atlas Wealth LLC | 19,620 | 0.00% | $1.36K | – | 0.00% |
| Financial Symmetry Inc | 10,191 | 0.00% | $707 | – | 0.00% |
| Huntington National Bank | 1 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q1 2026 | 6 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q3 2025 | 7 | 0M | 0.1% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q2 2025 | 7 | 0M | 0.1% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 7 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 6 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2024 | 7 | 0M | 0.1% | 0 / 0 | 2 / 0 | 0M | 0M |
| Q2 2024 | 7 | 0M | 0.1% | 1 / 1 | 0 / 0 | 0M | 0M |
| Q1 2024 | 6 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 7 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 6 | 0M | 0.1% | 0 / 0 | 0 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Edward Pershing | CEO, Director, 10% owner | 3,532,980 | 0.84% | Nov 16, 2026 |
| Dominic Rodrigues | PRESIDENT, Director | 1,201,214 | 0.29% | Jun 30, 2026 |
| Eric Wachter Phd | CTO | 6,649,298 | 1.58% | Dec 4, 2024 |
| Heather Raines | CFO | 1,213,153 | 0.29% | Dec 4, 2024 |
| John Lacey III | Director | 200,450 | 0.05% | Jun 30, 2026 |
| Webster Bailey | Director | 145,528 | 0.03% | Jun 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Allen Morris 10% owner | Aug 12, 2024 | Conversion | +264,314 | $2.86 | $755.94K | 4,260,061 |
| Jeffrey Allen Morris 10% owner | May 8, 2023 | Conversion | +188,757 | $2.86 | $539.85K | 3,995,747 |
| Heather Raines CFO | Nov 10, 2020 | Award | +50,000 | – | – | 1,213,153 |
| Bruce Horowitz Chief Operating Officer, Director | Nov 10, 2020 | Award | +800,000 | – | – | 2,227,243 |
| John Lacey III Director | Nov 10, 2020 | Award | +100,000 | – | – | 200,000 |
| Heather Raines Chief Financial Officer | Mar 25, 2019 | Award | +50,000 | – | – | 1,163,153 |
| John R. Glass See Remarks | Dec 14, 2017 | Buy | +115,900 | $0.05 | $5.80K | 200,000 |
| John R. Glass See Remarks | Dec 14, 2017 | Buy | +84,100 | $0.05 | $4.21K | 84,100 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +133,333 | $1.00 | $133.33K | 1,384,496 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +27,333 | $1.00 | $27.33K | 1,411,829 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +106,000 | $1.00 | $106.00K | 296,503 |
| Eric Wachter Phd Chief Technology Officer, Director | Mar 29, 2016 | Exercise | +106,000 | $1.00 | $106.00K | 930,248 |
| Eric Wachter Phd Chief Technology Officer, Director | Mar 29, 2016 | Exercise | +200,947 | $1.00 | $200.95K | 5,714,183 |
| Jan Koe Director | Mar 29, 2016 | Exercise | +100,000 | $1.25 | $125.00K | 786,300 |
| Jan Koe Director | Mar 29, 2016 | Exercise | +100,000 | $1.25 | $125.00K | 686,300 |
| Eric Wachter Phd Chief Technology Officer | Dec 21, 2015 | Option exercise | +120,000 | $1.02 | $122.40K | 5,513,236 |
| Peter R. Culpepper CFO & COO | Dec 9, 2015 | Option exercise | +138,831 | $0.94 | $130.50K | 1,251,163 |
| Peter R. Culpepper CFO & COO | Dec 9, 2015 | Option exercise | +6,383 | $0.94 | $6.00K | 190,503 |
| Eric Wachter Phd Chief Technology Officer | Jan 24, 2015 | Option exercise | +185,000 | $1.02 | $188.70K | 824,248 |
| Timothy Scott Phd President, Director | Jan 7, 2015 | Option exercise | +76,764 | $0.64 | $49.13K | 503,125 |
| Peter R. Culpepper CFO & COO | Jan 7, 2015 | Option exercise | +33,334 | $0.75 | $25.00K | 154,334 |
| Peter R. Culpepper CFO & COO | Jan 7, 2015 | Option exercise | +29,786 | $0.94 | $28.00K | 184,120 |
| Timothy Scott Phd President, Director | Dec 30, 2014 | Option exercise | +126,361 | $0.64 | $80.87K | 426,361 |
| Timothy Scott Phd President, Director | Oct 29, 2014 | Option exercise | +96,875 | $0.64 | $62.00K | 1,521,845 |
| Peter R. Culpepper CFO & COO | Jun 28, 2014 | Option exercise | +100,000 | $1.25 | $125.00K | 1,112,332 |
| Timothy Scott Phd President | May 19, 2014 | Option exercise | +25,000 | $0.95 | $23.75K | 1,424,970 |
| Timothy Scott Phd President | May 19, 2014 | Option exercise | −25,000 | $0.95 | $23.75K | 1,424,970 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +25,000 | $0.95 | $23.75K | 5,418,236 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +600,000 | $0.93 | $558.00K | 6,032,484 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +14,248 | $0.75 | $10.69K | 5,432,484 |
| Timothy Scott Phd President | Feb 26, 2014 | Option exercise | +300,000 | $1.10 | $330.00K | 300,000 |
| Peter R. Culpepper CFO & COO | Feb 26, 2014 | Option exercise | +68,624 | $1.10 | $75.49K | 1,012,332 |
| Peter R. Culpepper CFO & COO | Feb 26, 2014 | Option exercise | +121,000 | $1.10 | $133.10K | 121,000 |
| Jan Koe Director | Sep 20, 2013 | Buy | +100,000 | – | – | 586,300 |
| H. Craig Dees Chief Executive Officer, Director | May 29, 2013 | Option exercise | +18,750 | $0.32 | $6.00K | 1,472,859 |
| H. Craig Dees Chief Executive Officer, Director | May 29, 2013 | Option exercise | +25,000 | $0.60 | $15.00K | 1,497,859 |
| Peter R. Culpepper CFO, COO | Dec 3, 2012 | Buy | +133,333 | – | – | 943,708 |
| Peter R. Culpepper CFO, COO | Nov 16, 2012 | Buy | +133,333 | – | – | 810,375 |
| Eric Wachter Phd Chief Technology Officer | Nov 16, 2012 | Buy | +666,666 | – | – | 5,393,236 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 5, 2011 | Option exercise | +100,000 | $0.75 | $75.00K | 4,726,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 1, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,626,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Nov 23, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,526,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Oct 19, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,426,570 |
| Timothy Scott Phd President, Director | Oct 6, 2011 | Option exercise | +25,000 | $0.60 | $15.00K | 1,399,970 |
| Timothy Scott Phd President, Director | Oct 6, 2011 | Option exercise | +75,000 | $0.32 | $24.00K | 1,374,970 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Sep 7, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,326,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Jul 29, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,226,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | May 3, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,126,570 |
| Peter R. Culpepper Chief Financial Officer | May 3, 2011 | Option exercise | +133,333 | $0.75 | $100.00K | 677,042 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 20, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,026,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 12, 2011 | Option exercise | +150,000 | $1.00 | $150.00K | 3,926,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Feb 7, 2011 | Option exercise | +8,333 | $0.75 | $6.25K | 3,776,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Feb 3, 2011 | Option exercise | +125,000 | $0.75 | $93.75K | 3,768,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 29, 2010 | Option exercise | +400,000 | $1.00 | $400.00K | 3,643,237 |
| Peter R. Culpepper Chief Financial Officer | Dec 29, 2010 | Option exercise | +133,333 | $0.75 | $100.00K | 543,709 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Nov 19, 2010 | Option exercise | +100,000 | $1.00 | $100.00K | 3,243,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Sep 7, 2010 | Option exercise | +100,000 | $1.00 | $100.00K | 3,143,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Jul 9, 2010 | Option exercise | +75,000 | $1.10 | $82.50K | 3,043,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 28, 2010 | Option exercise | +52,419 | $0.75 | $39.31K | 2,968,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 28, 2010 | Option exercise | +105,469 | $0.64 | $67.50K | 2,915,818 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Provectus Biopharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?